Devika Kapuria

ORCID: 0000-0003-1000-5596
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Gastrointestinal disorders and treatments
  • Immunodeficiency and Autoimmune Disorders
  • Liver Disease and Transplantation
  • Hepatitis Viruses Studies and Epidemiology
  • Immune Cell Function and Interaction
  • Hematopoietic Stem Cell Transplantation
  • Genetic and Kidney Cyst Diseases
  • Thermoregulation and physiological responses
  • Prion Diseases and Protein Misfolding
  • Pediatric Hepatobiliary Diseases and Treatments
  • Diverticular Disease and Complications
  • Adipokines, Inflammation, and Metabolic Diseases
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Organ Transplantation Techniques and Outcomes
  • Exercise and Physiological Responses
  • Neutropenia and Cancer Infections
  • Cytomegalovirus and herpesvirus research
  • Eosinophilic Esophagitis
  • Metastasis and carcinoma case studies
  • Adipose Tissue and Metabolism
  • T-cell and B-cell Immunology
  • Urological Disorders and Treatments

National Institute of Diabetes and Digestive and Kidney Diseases
2017-2022

National Institutes of Health
2017-2022

University of New Mexico
2019

University of Missouri–Kansas City
2015-2017

BACKGROUNDMirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white (WAT) lipolysis, and insulin sensitivity.METHODSWe treated 14 healthy women diverse ethnicities (27.5 ± 1.1 years age, BMI 25.4 1.2 kg/m2) with 100 mg mirabegron (Myrbetriq extended-release tablet,...

10.1172/jci131126 article EN Journal of Clinical Investigation 2020-01-21

X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia (XMEN) disease are caused by deficiency of the transporter 1 (MAGT1) gene. We studied 23 patients XMEN, 8 whom were naive. observed lymphadenopathy (LAD), cytopenias, liver disease, cavum septum pellucidum (CSP), increased CD4-CD8-B220-TCRαβ+ T cells (αβDNTs), in addition to previously described features an inverted CD4/CD8 ratio, CD4+ lymphocytopenia, B cells, dysgammaglobulinemia, decreased expression natural...

10.1172/jci131116 article EN Journal of Clinical Investigation 2019-11-12

The deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessively inherited disease that has undergone extensive phenotypic expansion since being first described in patients with fevers, recurrent strokes, livedo racemosa, and polyarteritis nodosa 2014. It now recognized may develop multisystem spans multiple medical subspecialties. Here, we describe the findings from a large single center longitudinal cohort 60 patients, broad presentation, as well highlight cohort’s experience...

10.3389/fimmu.2021.811473 article EN cc-by Frontiers in Immunology 2022-01-10

Da, Ben L.; Surana, Pallavi; Kapuria, Devika; Vittal, Anusha; Levy, Elliot; Kleiner, David E.; Koh, Christopher; Heller, Theo Author Information

10.1002/hep.30862 article EN Hepatology 2019-07-18

10.1016/j.cgh.2015.12.035 article EN Clinical Gastroenterology and Hepatology 2016-01-05

ABSTRACT Granulocyte-colony-stimulating factors such as filgrastim are currently used for multiple indications, one of which is administration to healthy donors allogeneic stem cell collection. So far, has not been described a cause drug-induced liver injury. We report case injury secondary use in 54-year-old donor. The patient presented with an upsurge enzymes week from the drug rapid downtrend over next few weeks. wish highlight possibility similar idiosyncratic adverse reaction other individuals.

10.14309/crj.0000000000000098 article EN cc-by-nc-nd ACG Case Reports Journal 2019-06-01

1Liver Disease BranchNational Institutes of HealthBethesdaMD 2Department GastroenterologyUniversity New MexicoAlbuquerqueNM * Address Correspondence and Reprint Requests to: Devika Kapuria, M.D. Department Gastroenterology, MSC 10‐5550 1 University Mexico Albuquerque, NM 87131 E‐mail: [email protected] Tel.: +1‐505‐272‐4205

10.1002/hep.31073 article EN Hepatology 2019-12-24

Abstract Hepatic graft‐versus‐host disease (HGVHD) contributes significantly to morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Clinical findings liver biomarkers are neither sensitive nor specific. The relationship between clinical histologic diagnoses of HGVHD was assessed premortem at autopsy. Medical records from patients who underwent HSCT the National Institutes Health (NIH) Center 2000 2012 expired with autopsy were reviewed, laboratory tests within 45...

10.1002/hep4.1965 article EN cc-by-nc-nd Hepatology Communications 2022-05-09

Pancreatic chronic inflammation often leads to glandular neoplasia. Upregulation of Maspin is a prognostic marker specific for this organ. This study evaluates pancreatic histopathological changes in model leptin knock out obese (ob/ob) mice determine their expression Maspin. Ten (controls) received normal diet and ten more we added Ω3 (20% EPA, 50% DHA) food pellets giving them daily dose similar an adult human 4 grams per day. At necropsy (2 months later) pancreases livers were collected...

10.1096/fasebj.29.1_supplement.767.2 article EN The FASEB Journal 2015-04-01

Letters17 October 2017A Misleading Pattern of Serologic Findings During Hepatitis B Virus InfectionGil Ben-Yakov, MD, Kapuria Devika, Ohad Etzion, Christopher Koh, MHSc, and Theo Heller, MDGil MDFrom National Institute Diabetes Digestive Kidney Diseases, Institutes Health, Bethesda, Maryland.Search for more papers by this author, MHScFrom authorAuthor, Article, Disclosure Informationhttps://doi.org/10.7326/L17-0369 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack...

10.7326/l17-0369 article EN Annals of Internal Medicine 2017-08-28

Question The hepatitis D virus (HDV) causes the most severe form of chronic hepatitis, often progressing to cirrhosis within 5-10 years. There is no curative treatment and mechanisms responsible for accelerated liver disease progression are unknown.

10.1055/s-0040-1722074 article EN Zeitschrift für Gastroenterologie 2021-01-01
Coming Soon ...